Aligos Therapeutics, Inc.

Listed Company

ALGSCIK 0001799448NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

$2.19M

Net Income

$-24.19M

Total Assets

$88.53M

Equity

$53.55M

Shares Out

6.18M

Op. Cash Flow

$-82.50M

Business

Aligos Therapeutics, Inc. is a clinical‑stage biotechnology company developing novel therapeutics to address unmet medical needs in liver diseases and viral infections. Its main product candidates include ALG‑000184 (a capsid assembly modulator for chronic HBV), ALG‑055009 (a THR‑β agonist for MASH), ALG‑097558 (a ritonavir‑free pan‑coronavirus protease inhibitor), siRNA programs such as ALG‑125755, and a portfolio of preclinical candidates. The company operates research and development platforms in small molecules, peptidomimetics and oligonucleotides and pursues collaborations and licensing arrangements. Its programs advance through clinical trials with plans for independent commercialization in select markets and potential partnerships, relying on third‑party contractors for manufacturing and distribution.

Summary from filing dated 2025-03-10

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue from collaborations	0	334,000	9	14	4
Revenue from customers	2	4	6	—	—
Research and development	69	70	73	85	104
General and administrative	21	23	31	26	29
Total operating expenses	90	93	104	111	133
Loss from operations	−88	−89	−88	−98	−128
Interest and other income, net	4	4	3	2	132,000
Change in fair value of 2023 Common Warrants	60	−46	−2	—	—
Loss before income tax	−24	−131	−87	−96	−128
Income tax provision	−314,000	−331,000	−795,000	−106,000	−143,000
Net loss	−24	−131	−88	−96	−128
Unrealized gain on available-for-sale securities	22,000	9,000	96,000	−57,000	—
Unrealized loss on pension plans	−5,000	−103,000	48,000	6,000	749,000
Other comprehensive income (loss)	17,000	−94,000	144,000	−51,000	—
Comprehensive loss	−24	−131	−88	−96	−128
Net loss per share, basic	−2.45	−20.94	−34.2	−2.25	—
Net loss per share, diluted	−2.45	−20.94	−34.2	−2.25	—
Weighted average shares of common stock, basic	10	6	3	43	—
Weighted average shares of common stock, diluted	10	6	3	43	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	18	37	136	81	187
Restricted cash	100,000	100,000	100,000	100,000	200,000
Short-term investments	60	20	—	44	4
Other current assets	5	5	5	8	14
Total current assets	83	62	141	134	204
Operating lease right-of-use assets	3	5	7	8	9
Property and equipment, net	2	2	3	5	6
Other assets	715,000	627,000	625,000	634,000	866,000
Total assets	89	70	152	147	235
Accounts payable	4	3	3	5	3
Accrued liabilities	14	16	17	16	25
Operating lease liabilities, current	4	3	3	3	3
Finance lease liabilities, current	145,000	36,000	10,000	108,000	138,000
Deferred revenue, current	0	151,000	1	—	—
Total current liabilities	21	22	24	33	39
Operating lease liabilities, net of current portion	2	5	8	9	11
Finance lease liabilities, net of current portion	0	122,000	231,000	230,000	261,000
2023 Common Warrants liability	12	72	—	—	—
Long term liability	47,000	46,000	46,000	—	133,000
Total liabilities	35	99	59	43	51
Commitments and contingencies (Note 12)	—	—	—	—	—
Preferred Stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; no shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively.	0	0	—	—	—
Common stock, $0.0001 par value; 115,800,000 shares and 20,800,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 6,178,230 and 3,864,436 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	9,000	8,000	7,000	4,000	4,000
Additional paid-in capital	695	589	578	503	487
Accumulated deficit	−642	−618	−487	−399	−303
Accumulated other comprehensive income	468,000	451,000	545,000	401,000	452,000
Total stockholders' equity (deficit)	54	−29	92	104	185
Total liabilities and stockholders' equity (deficit)	89	70	152	147	235

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Accretion of discount on investments	−2	−2	−424,000	−159,000	86,000
Non cash lease expense	2	2	2	1	759,000
Change in fair value of 2023 Common Warrants	−60	46	2	—	—
Depreciation expense	900,000	1	2	2	3
Stock-based compensation including ESPP	5	8	13	15	13
Accounts payable	1	54,000	−2	2	−313,000
Accrued liabilities	−2	−1	918,000	−9	10
Operating lease liabilities	−3	−3	−2	−2	−1
Deferred revenue	−151,000	−1	−8	3	−4
Other assets	96,000	216,000	2	6	−8
Net cash and cash equivalents used in operating activities	−83	−81	−79	−79	−116
Maturities of short-term investments	128	90	45	79	23
Purchase of short-term investments	−165	−108	−11,000	−104	−3
Purchases of property and equipment	−437,000	−130,000	—	—	—
Net cash and cash equivalents used in investing activities	−38	−18	45	−26	3
Proceeds from issuance of common stock upon exercise of pre-funded warrants	—	2,000	—	—	—
Proceeds from issuance of common stock, common warrants and pre-funded warrants in connection with PIPE offering, net of costs	101	—	—	—	—
Payments on finance lease	−14,000	−83,000	−96,000	−61,000	−79,000
Proceeds from the ESPP purchase	304,000	436,000	551,000	205,000	—
Net cash and cash equivalents provided by financing activities	102	355,000	88	164,000	79
Net decrease in cash, cash equivalents, and restricted cash	−19	−99	54	−106	−34

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro